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The hygiene hypothesis postulates that higher levels of cleanliness and improper 
exposure to microorganisms early in childhood could disturb the intestinal microbiome 
resulting in abnormal immune responses. Recently, more attention has been put on how 
a lack of sun exposure and consequently vitamin D deficiency could lead to less immune 
tolerance and aberrant immune responses. Moreover, vitamin D receptor (VDR) function 
has been positioned to be a critical aspect of immune response and gut homeostasis. 
Therefore, this review focuses on the role that the interaction between vitamin D, VDR 
function, and gut microbiome might have on autoimmune diseases in the context of the 
hygiene hypothesis. Literature shows that there is a high correlation between vitamin D 
deficiency, VDR dysfunction, gut microbiota composition, and autoimmune diseases. 
The biologically active form of vitamin D, 1,25(OH)2D3, serves as the primary ligand for 
VDRs, which have been shown to play a fundamental role in reducing autoimmune 
disease symptoms. Although the biological functions of VDR, the effects of its genetic 
variants, and the effects of epigenetic profiles in its promoter region are largely unknown 
in humans, studies in murine models are increasingly demonstrating that VDRs play a 
crucial role in attenuating autoimmune disease symptoms by regulating autophagy and 
the production of antimicrobial peptides, such cathelicidin and β-defensin, which are 
responsible for modifying the intestinal microbiota to a healthier composition. Remarkably, 
evidence shows that hormonal compounds and byproducts of the microbiota such as 
secondary bile acids might also activate VDR. Therefore, understanding the interaction 
between VDR and gut microbiota is of the utmost importance toward understanding the 
Abbreviations: AMPs, antimicrobial peptides; ATG5, autophagy-related 5; ATG16L1, autophagy-related 16 like 1; BPA, bis-
phenol A; CAMP, cathelicidin antimicrobial peptide; CCL22, C–C motif chemokine ligand 22; Cyp24, 25-hydroxyvitamin D 
24-hydroxylase; CYP27A1, cytochrome P450 family 27 subfamily member 1; CYP27B1, cytochrome P450 family 27 subfamily 
B member 1; D3, 1,25-dihydroxyvitamin D3; DCs, dendritic cells; DSS, dextran sulfate sodium; GALT, gut-associated lymphoid 
tissue; INF-γ, interferon gamma; IL, interleukin; IBD, irritable bowel disease; KO, knockout; LD, linkage disequilibrium; LPS, 
lipopolysaccharide; MS, multiple sclerosis; NF-kB, nuclear factor kappa light chain enhancer of B cells; Nod2, nucleotide-
binding oligomerization domain 2; NR5A2, nuclear receptor subfamily 5 group A member 2; PPAR, peroxisome proliferator 
activated receptor; PRRs, pattern recognition receptors; SCFA, short chain fatty acids; SNP, single-nucleotide polymorphism; 
Th1, T helper 1; Th2, T helper 2; Th17, T helper 17; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha; Treg, regulatory 
T cell; UVB, ultraviolet B rays; VDR, vitamin D receptor; VDREs, vitamin D responsive elements; D3, 1,25(OH)2D3; ZO-1, 
zonulin occluden-1; ZO-2, zonulin occluden-2.
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rise in autoimmune diseases in Western countries. We have gained insights on how the 
VDR functions affects inflammation, autophagy, and microbiota composition that could 
lead to the development of pathogenesis of autoimmune diseases, while confirming the 
role vitamin D and VDRs have in the context of hygiene hypothesis.
Keywords: vitamin D, vitamin D deficiency, vitamin D receptor, gut microbiota, hygiene hypothesis, autoimmune 
diseases, western lifestyle
iNTRODUCTiON
Strachan developed the hygiene hypothesis in 1989 with the 
notion that viral infections early in life and family size affect the 
risk of suffering from hay fever and allergic rhinitis (1). Since 
then, it has been suggested that the increased cleanliness and 
subsequent lack of proper microbial exposure in early childhood, 
a common occurrence in Western society, can disrupt the human 
microbiome causing a lack of indigenous microbes and aberrant 
immune responses (2–4).
An international systematic review on vitamin D, the gut 
microbiome, and the hygiene hypothesis (5) suggested that lim-
iting the hygiene hypothesis to excessive cleanliness and early 
life infections does not fully explain the rise in autoimmune dis-
eases or the susceptibility to asthma in Western countries. They 
postulated that less sun exposure and thus vitamin D deficiency 
as well as reduced exposure to ancient and beneficial microor-
ganisms that “train” our immune systems from the uterus to 
postnatal life are inversely associated with immune tolerance 
and gut microbiota diversity (5). The critical role of vitamin D 
on the gut microbiome and developing fetal lung and immune 
system has been reviewed by the same authors (6); however, 
beyond vitamin D deficiency, we noted that the relationship 
between vitamin D receptor (VDR) functions, gut microbiota, 
and the rise in autoimmune diseases had not yet been exten-
sively explored. With specific focus on the interaction between 
vitamin D, VDRs, gut microbiota, and immune responses, this 
review will allow greater understanding of how this interaction 
could lead to the development of an autoimmune disease. We 
hypothesize that the increasing rates of vitamin D deficiency 
coupled with VDR dysfunction and a lack of gut microbiota 
diversity are the key drivers of the rise in autoimmune diseases 
in Western countries.
MATeRiALS AND MeTHODS
We conducted a systematic review and synthesis of relevant 
qualitative research according to the requirements established 
in the preferred reporting items for systematic review and meta-
analysis protocols (7). The protocol was registered a priori with 
PROSPERO on April 11, 2016 (CRD42016037431).
eligibility Criteria and Literature  
Search Strategy
A systematic and comprehensive search of electronic databases, 
including MEDLINE, Scopus, http://ClinicalTrials.gov, the 
PROSPERO International Prospective Register of Systematic 
Reviews, Science Direct, Springer Link, and EMBASE was done 
from March 2016 to September 2016.
The search process was completed using the keywords: 
“hygiene hypothesis,” “gut microbiota,” “microbiota heritability,” 
“vitamin D,” “VDR,” “autoimmune disease,” and “immune toler-
ance.” The search was not restricted to the type of study (i.e., 
species, meta-analysis, case–control, prospective cohort studies, 
and reviews), sample size, year of publication, publication status, 
or follow-up. However, we only consulted articles published in 
English. Bibliographies of the identified reviews and original 
research publications were hand selected for additional studies 
that may have been missed by the database searches. All articles 
were exported to the reference database Zotero. Due to the nature 
of this review, no request was performed for the ethics commit-
tee’s approval.
Data extraction and Synthesis
Full copies of citations coded as potentially relevant were 
obtained, and those meeting the inclusion criteria were read in 
detail and data were extracted. One reviewer (Allison Clark) 
extracted information about the study aim, population and 
sample size, experimental design and duration of follow-up, 
species, individual characteristics, changes in the gut microbiota 
composition, and immune response and association or not with 
an autoimmune disease. The primary outcome was the gut micro-
biota profile, aberrant changes in the immune response, vitamin 
D status, VDR functions, or other clinically relevant outcomes 
related to autoimmune and immune-related conditions. Details 
were then checked by a second reviewer (Núria Mach). If eligibil-
ity could be determined, the full article was retrieved.
The articles and extracted data were read and the findings were 
organized into the following categories: (i) hygiene hypothesis, 
the gut microbiota, and the immune system; (ii) experimental 
articles about the possible relationship between disturbances of 
the gut microbiota and/or vitamin D3 deficiency, VDR dysfunc-
tion, and autoimmune diseases.
Data Synthesis
A search conducted in March 2016 resulted in the following list 
of key terms combinations (hygiene hypothesis, the gut micro-
biota, and autoimmune disease = 5; vitamin D and autoimmune 
disease = 18; vitamin D3, VDR function, intestinal microbiota, 
and autoimmune diseases = 16). A total of 47 experimental stud-
ies and 54 reviews met the inclusion criteria and were included 
in the review. Most of the articles were reviews or randomized 
controlled trials. Periods of data collection spanned from 1989 to 
2016, proving data from humans and animals models (i.e., mice 
and rats).
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DiSCUSSiON
Hygienic western Lifestyle and its effects 
on the Gut Microbiome
Most studies about the hygiene hypothesis have focused on the 
depletion of indigenous microbiome diversity in the modern 
world and the rise of autoimmune disease prevalence (8). The 
human microbiome is the “forgotten organ” and is as unique as 
a fingerprint (9). Humans are home to a complex ecosystem of 
trillions of microbes such as archaea, small eukaryotes, fungi, 
parasites, viruses, and yeast (10). The gut microbiota is essential 
for host immune function, nutrient digestion, short chain fatty 
acids (SCFAs) production, vitamin synthesis, energy metabolism, 
intestinal permeability, protection from pathogens, and determin-
ing the host’s susceptibility to gastrointestinal  infections (11, 12).
Commensal microorganisms, pathogens, and nutrients that 
pass through the intestinal lumen are the first point of contact 
with the enteric immune system, which plays a critical role in 
innate and adaptive immunological functions (13,  14). A con-
stant cross talk occurs between intestinal epithelial cells, gut 
microbiota, and the gut-associated lymphoid tissue, which is 
mainly composed of Peyer’s patches, lymphoid nodules embed-
ded in the submucosa of the small intestine, and lymphocytes 
distributed throughout the lamina propria (15). Epithelial cells, 
dendritic cells (DCs) located in Peyer’s patches and macrophages 
within the lamina propria present pattern recognition receptors 
such as toll-like receptor and nucleotide-binding oligomerization 
domain 2 (Nod2) receptors, which are responsible for different 
immune responses when facing dysbiosis or abiotic stress (16). 
Therefore, the gut microbiota is believed to be crucial for proper 
host immune development and response (17) and plays a key role 
in building up the host’s tolerance to foreign antigens (5).
The shift from Paleolithic times to industrialization has greatly 
affected the human microbiome, which is believed to be due 
to certain hygienic practices (18, 19). According to the review 
conducted by Rook (19), a hygienic lifestyle and cleanliness can 
generally be defined as an abuse of antibiotic and dewormer treat-
ments that can decrease immune tolerance, antibacterial soaps 
and cleaners, drinking chlorinated water, and delayed exposure 
to viruses among newborns coupled with an excessive time spent 
indoors. All these practices can deplete indigenous microorgan-
isms or “Old Friends” that help regulate the immune system 
(19). A hygienic lifestyle can also lead to decreased exposure to 
indigenous viruses such as Hepatitis A, pathogenic bacteria such 
as Heliobacter pylori, Salmonella spp., Mycobacterium tubercu-
losis, and parasites like helminths and Toxoplasma gondii (19). 
Anecdotal evidence has shown that parasitic infection diminishes 
or eliminates allergic reactions (11) probably because helminths 
can modulate the gut microbiota and DCs toward a more tolero-
genic phenotype (20). For example, Nod2 knockout (KO) mice 
showed that intestinal helminth infection prevented the coloni-
zation of inflammatory Bacteriodes vulgatus and promoted the 
colonization of protective microbiota enriched in Clostridiales, 
which was caused by a T helper cell type 2 immune response (21). 
On the other hand, dewormer treatment decreased Clostridiales 
and increased Bacteroidales (21).
Studies comparing the fecal microbiota of indigenous popula-
tions vs. Westerners have shown that an overly hygienic lifestyle 
leads to less microbial diversity of the gut microbiota (22). In a 
landmark study of the Yanomami indigenous group who live in 
a rural area of the Amazon, Clemente et al. (23) discovered that 
these people who do not have an excessively hygienic lifestyle, 
spend hours outside, and do not take antibiotics presented 50 
times more gut microbiome diversity than Americans and also 
suffered less autoimmune diseases. Additionally, indigenous 
diets tend to be much higher in dietary fiber, which can lead to a 
healthier gut microbiota composition that is lower in Firmicutes 
and higher in Bacteroidetes and the anti-inflammatory micro-
biota byproducts SCFAs (24). Dietary changes can account for 
up to 57% of gut microbiota changes, whereas the human genome 
accounts for no more than 12% (25), which could explain why 
Westerners have less microbial diversity in the gut given that the 
Western diet is characteristically low in fiber which can lead to 
less microbiota diversity (26, 27).
In summary, literature shows that a hygienic Western lifestyle 
can reduce gut microbial diversity (28) leading to “over zealous” 
immune responses, which could explain the increase in autoim-
mune diseases (Figure  1). However, autoimmune diseases, 
which are characterized by a loss of self-antigen tolerance (29) 
and increased auto-antibodies and/or auto-reactive lymphocytes 
(30), depend not only on the gut microbiota diversity and func-
tion but also on other factors such as vitamin D deficiency (5, 31) 
and VDR functions to regulate immune responses [Figure  1; 
(32, 33)].
vitamin D Deficiency, the immune System, 
and Gut Microbiota
As reviewed by Litonjua and Weiss (6), vitamin D not only helps 
regulate calcium levels, blood pressure, and electrolytes, it is 
also an essential component of our immune system. Vitamin D 
deficiency is a contributing factor to the increasing rates of auto-
immune diseases such as rheumatoid arthritis, systematic lupus 
erythematosus, multiple sclerosis (MS), type I diabetes, irritable 
bowel disease (IBD), and other autoimmune diseases (43).
Western society’s lifestyle has led to people spending more 
time indoors and thus having less sun exposure which is believed 
to be a major cause of vitamin D deficiency (44). While diet can 
provide up to 10–20% of the human body’s requirements for 
vitamin D, ~90% of all needed vitamin D has to be photosyn-
thesized in the skin through ultraviolet B rays [UVB; Figure 2; 
(45)]. The rays hit the skin converting 7-dehyrocholesterol into 
pre-vitamin D3, which is then isomerized into cholecalciferol 
or D3 (46). For this reason, vitamin D synthesis from solar rays 
can be affected by latitude, air pollution, season, time of the day, 
sunscreen use, and skin pigmentation (39). Vitamin D-binding 
protein binds to D3, which reaches the dermal capillary bed 
where it gets transferred from the bloodstream to the liver (39). 
On the other hand, ingested vitamin D2 or ergocalciferol passes 
through the small intestines and binds to chylomicrons, which 
enter the lymphatic system, and then bloodstream where they 
are transferred to the liver. In the liver, both vitamin D2 and 
vitamin D3, are hydroxylated by the enzyme cytochrome P450 to 
FiGURe 2 | vitamin D3 synthesis from sun exposure and food. Vitamin D is synthesized from sun exposure or consumption of foods rich in vitamin D. The 
ultraviolet B rays from the sun at frequencies between 280 and 320 hit the skin where 7-dehydrocholesterol is converted into pre-vitamin D3 and is then isomerized 
into vitamin D3 or cholecalciferol (46). Vitamin D-binding protein then facilitates vitamin D3’s entrance into the dermal capillary bed (39). On the right of the figure, 
ingested vitamin D2 (ergocalciferol) from food or supplements is incorporated into chylomicrons, which enter the lymphatic system and blood. Once in the 
bloodstream, both vitamin D2 and vitamin D3 move to the liver where the enzyme cytochrome P450 hydroxylates both forms of the vitamin to 25(OH)D3. Then, the 
CYP27B1 further hydroxylates 25(OH)D3 into the active form of the vitamin [1,25(OH)2D3] in the kidneys (39). Unlike D2 or other vitamin D metabolites, vitamin D3 is 
the active form of vitamin D that binds to the vitamin D receptor (VDR), which is located in about 30 different tissues (47). The activated VDR binds to vitamin D 
responsive elements (VDREs) to form a heterodimer (48), which can regulate directly or indirectly the expression of ~3% of the mouse and human genomes (49).
FiGURe 1 | western lifestyle factors that lead to autoimmunity diseases. The figure represents the main factors that contribute to the disruption of gut 
homeostasis and rise in autoimmune diseases in Western countries, such as stress, a hyper-hygienic lifestyle that includes deworming treatments at an early age, 
drinking chlorinated water (19), and excessive antibiotic treatments (34), the Western diet which is characteristically low in fiber and high in saturated fat (35), toxins 
(36), drugs (36–38), and vitamin D deficiency (39). Furthermore, Vitamin D deficiency and vitamin D receptor function have also been shown to disrupt gut 
homeostasis and consequently immune tolerance (40, 41). All of these factors can lead to intestinal dysbiosis, more susceptibility to pathogenic infections and 
intestinal permeability, which predispose to lipopolysaccharides translocation and trigger inflammatory immune responses such as TNF-α and IFN-γ (42). The loss of 
immune homeostasis can lead to food intolerances and allergies, which can subsequently lead to autoimmune disease development (19).
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25-hydroxyvitamin D3 (25(OH)D3). Then, the 25(OH)D3 is fur-
ther converted to 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], the 
hormonally active secosteroid, by the 1-α-hydroxylase enzyme 
cytochrome P450 family 27 subfamily B member 1 (CYP27B1), 
primarily in the kidneys (39). Finally, 1,25(OH)2D3 binds to the 
VDR, which is located in about 30 different tissues (47) and can 
regulate the expression of more than 1,000 genes in the genome 
(Figure 2). For further details on the biological functions of VDR, 
see section “Discussion.”
Generally, the ingestion of 1,000 IU vitamin D2/day increases 
the 1,25(OH)2D3 levels ~10 ng/mL, though individual results may 
vary (31). An adult exposed to 1 minimal erythemal dose (slight 
pinkness to the skin 24 h after exposure) is equivalent to an oral 
intake of 20,000 IU (500 µg) of vitamin D2 (31). Whereas arm and 
leg exposure of 0.5 erythemal dose is equivalent of oral intake of 
3,000 IU of vitamin D2 (39). About 20 min of sun exposure on the 
arms and face between latitudes 42°N and 42°S is equivalent to 
200–400 IU of vitamin D3 ingestion (50).
Besides the sun, exposure to endocrine disrupting chemi-
cals such as bisphenol A and phlalates, which are widely used 
industrial compounds found in several commercial products, 
may alter serum 25(OH)D3, which is the metabolite of vitamin D 
used to measure vitamin D levels in adults. These chemicals have 
been found to modify the expression of cytochrome P450 and 
CYP27B1 genes in mice (51). Therefore, exposure to common 
chemicals found in Western society may also be a contributing 
factor to the rise in vitamin D deficiency.
Approximately one billion people worldwide suffer from 
vitamin D deficiency (47), which is generally defined as <20 ng/
mL (50 nmol/L) (52). An estimated 20–80% of the population in 
the Canadian and European population is vitamin D deficient 
while approximately one-third of the U.S. population is deficient 
(39), yet there is a surprising lack of research in Vitamin D 
deficiency in African and South American populations (53). The 
populations most at risk for suffering a deficiency are infants and 
children >5 years old, people 65 years and older, pregnant women 
(39), those with dark-skin color or who wear clothes that cover 
the whole body such as in the Middle East (54).
Furthermore, maternal vitamin D status can have a direct 
effect on fetal and infant immune programing. To date, multiple 
studies have reported that maternal vitamin D insufficiency 
and deficiency can also lead to child allergies (55, 56), eczema, 
asthma (57), and autoimmune diseases (58–60). Maternal serum 
25(OH)D3 levels can directly affect infant vitamin D levels and 
immune programing (54, 61), and interestingly 1,25(OH)2D3, can 
cross the placenta and enter the fetal cord blood (39). Maternal 
serum 25(OH)D3 levels directly correlate with concentrations in 
the umbilical cord at birth (62), suggesting that maternal vitamin 
D might influence fetal immune response and tolerance like 
regulatory T cells (Tregs) stimulation of the offspring (32). D3 
can also block lipopolysaccharides (LPS)-induced translocation 
of nuclear factor kappa light chain enhancer of B cells (NF-kB) 
p65 from the cytoplasm to the nuclei in placental cells, which 
prevents the activation of downstream target inflammatory 
genes (63).
Supplementing mothers with vitamin D have proven to be 
an effective method to ensure infant vitamin D sufficiency. 
Disanto et al. (58) performed a study in women from the UK and 
concluded that gestational UVB exposure could affect whether 
or not their offspring would suffer an immune-related disease 
such as colitis and MS due to vitamin D3 deficiency. In another 
study, mothers who were supplemented with 6,400  IU/day of 
vitamin D were able to effectively and safely provide their infant 
with adequate D3 through just breastfeeding (64). Interestingly, 
vitamin D supplementation induced the antimicrobial peptide 
(AMP), cathelicidin, which protected both mother and fetus from 
Staphylococcus epidermidis infections, which is a major cause of 
preterm sepsis (65).
Maternal vitamin D status is an important health concern 
that needs more attention especially since supplementation in 
the mother and/or infant has proven to be effective at improving 
serum 25(OH)D3 levels (56). For this reason, it is recommended 
that women who are pregnant or breastfeeding supplement daily 
with vitamin D in order to meet their daily recommended intake 
requirements to prevent deficiency and possibly avoid adverse 
pregnancy, birth, and offspring immune outcomes (31, 66). Some 
study outcomes have been inconclusive on the role of maternal 
vitamin D supplementation on the offspring’s immune program-
ing [(53, 67); Figure 2].
Other recent studies in humans have demonstrated that 
1,25(OH)2D3 may directly interact with the gut microbiota and 
ameliorate dysbiosis in autoimmune patients (68). In a cohort 
of 3,188 IBD patients, higher plasma 25(OH)D3 (27.1  ng/mL) 
was associated with significantly reduced risk of Clostridium 
difficile infection (68). Another study in MS patients showed that 
supplementing with 5,000 IU of vitamin D per day for 90 days 
increased the abundance of Akkermansia, which promotes 
immune tolerance, as well as Faecalibacterium and Coprococcus, 
which both produce butyrate, an anti-inflammatory SCFA (69). 
A case controlled study of 7 relapsing-remitting MS patients 
showed that vitamin D3 treatment caused changes in Firmicutes, 
Actinobacteria, and Proteobacteria levels in MS patients as well as 
an increase in Enterobacteria in healthy patients and MS patients 
compared to those who were not treated daily with D3 (70).
In animal models, a cross talk between vitamin D and the 
gut microbiota has also been proven. C57BL/6 mice raised on a 
vitamin D sufficient diet had 50 times more colonic bacteria and 
microbial diversity than mice raised on a vitamin D poor diet (71). 
In the same line, C57BL/6 mice that were raised from weaning on 
vitamin D deficient diets presented deregulated colonic contain-
ment of enteric bacteria, which the authors believe could be a pos-
sible mechanism behind colitis susceptibility (71). In addition, 
vitamin D deficient mice infected with Citrobacter rodentium 
demonstrated an altered fecal microbiome composition and 
increased colonic hyperplasia and intestinal barrier permeability 
(72). In another experiment, Cyp KO mice that could not produce 
1,25(OH)2D3 and received 1.25 μg/100g of food had reduced dex-
tran sulfate sodium (DSS)-induced colitis severity and decreased 
Helicobacteraceae abundance (73). Another study in naked mole 
rats (Heterocephalus gluber) that habitually live underground and 
thus receive little if any UVB exposure, were administered with 
25 ng of vitamin D2/g food every 3 days. The authors reported that 
rats had a 1.4-fold increase in cecal mass and in SCFA production 
per gram of dry matter compared to control animals, suggesting 
FiGURe 3 | vitamin D’s effect on the gut microbiota and immunity. The active form of vitamin D [1,25(OH)2D3] serves as the primary ligand for the vitamin D 
receptors (VDRs). The activated VDR binds to vitamin D responsive elements (VDREs) to regulate the expression of 3% of the genome (48). There are more than 
1,000 genes with binding sites for VDRE, including antimicrobial peptides such as cathelicidin, β-defensin, cathelicidin antimicrobial peptide, and defensin β2 (33, 
80). An activated VDR also regulates innate immune responses by controlling the genetic expression of toll-like receptor 2 (3), and nucleotide-binding oligomerization 
domain 2, which subsequently activates the transcription factor nuclear factor kappa light chain enhancer of activated B cells which induces defensin β2 gene 
expression (33). Activated VDR also plays a role in maintaining intestinal barrier function, which prevents lipopolysaccharides translocation and an ensuing 
inflammatory response by regulating the expression of the tight junction proteins zonulin occluden-1, zonulin occluden-2, claudin 2, and 12 in the intestine (75). 
VDRs can also inhibit the reduction in transepithelial electrical resistance by the pathogenic Escherichia coli O157:H7, which thus decreases intestinal permeability in 
epithelial cells (72). Furthermore, VDR promotes immune tolerance in the gut by inhibiting Th1 and Th17 cells proliferation, which produce IL-172 and IFN-γ 
production as dendritic cell-mediated IL-10 production, which increases regulatory T cell production promoting a T helper cell type 2 response (81, 82).
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that vitamin D can modify the gut microbiota and its byproducts 
leading to a healthier composition (74).
All these major discoveries make a compelling argument that 
vitamin D can alter the gut microbiota composition and function 
toward a more homeostatic state. Despite these findings, it is 
important to note that role of vitamin D and microbiota composi-
tion in autoimmune diseases is not as simple as just the presence 
or absence of a deficiency. 1,25(OH)2D3 and its metabolites are 
the results of many integrated enzymatic and non-enzymatic 
transformations with numerous intermediaries that are regulated 
by the host genome, epigenome, and lifestyle factors such as diet 
and sun and microorganisms exposure. Moreover, the activity 
of 1,25(OH)2D3 depends on the proper function of the VDRs, 
which can be regulated by gut bacteria, toxins, enteric bacteria-
produced bile acids, dietary fatty acids, and epigenetic changes, 
which will be discussed in more detail in the next section.
The interaction between vDRs, Gut 
Microbiota, and immune Response
Biological Functions of VDR
Various studies investigating the hygiene hypothesis have focused 
on the possible connection between vitamin D deficiency and the 
development of autoimmune diseases. As awareness increases 
about the influence vitamin D has on immune responses, attention 
has recently turned to how the VDR function might have a role in 
maintaining gut and immune homeostasis.
The VDR is a member of the nuclear receptor super family 
located in macrophages, DCs, activated T cells, and other types 
of cells in about 30 different tissues, including the intestines (47) 
and fetal tissues (75). The VDR is primarily activated by the 
binding of its primary ligand 1,25(OH)2D3 (76), and basically all 
biological actions of vitamin D are mediated by the VDR. The 
structure of the VDR incorporates an α-helical ligand-binding 
domain and a highly conserved DNA-binding domain (76). 
VDR, through heterodimerization with the retinoid-X receptor 
(RXR), then binds to vitamin D response elements (VDREs) in 
the regulatory region of target genes [(48); Figure  3]. VDREs 
are normally localized close to the promoter of genes, although 
evidence from recent research indicates VDR complex can oper-
ate over distances of 75 kb to regulate target gene transcription 
(77), increasing the potential of VDR complexes to regulate our 
genome (78). There are more than 1,000 genes with binding sites 
for VDRE, including AMPs such as cathelicidin (79), β-defensin 
(79), the 25-hydroxyvitamin D 24-hydroxylase (CYP24) gene, 
and cytochrome P450 family 11 subfamily A (CYP11A1) gene 
(78). In fact, ~3% of the mouse and human genomes are regulated 
directly or indirectly by VDRs (49), which may explain their role 
on preventing various diseases mechanisms (33), even in the fetal 
stage [(32); Figure 3].
TAbLe 1 | effects vitamin D and its biologically active form [1,25(OH)2D3] on the immune system.
immunological effect Reference
Anti-inflammatory effects
Promote the maturation, survival, and apoptosis of dendritic cells (DC), which is a key mechanism of the adaptive immune system (81)
Inhibit T cell proliferation, IL-2 and IFN-γ production, and T helper 1 (Th1) cells development (81)
Decrease B cells and antibody-secreting cells like IgG and IgM (91)
Promote regulatory T cell (Treg) proliferation by increasing C–C motif chemokine ligand 22 expression (47)
Regulate toll-like receptor (TLR)-2 expression (3)
Activate macrophages, DCs, and T cells (75)
Promote autoimmune homeostasis by stimulating Treg and inhibiting TLR8 activity (92)
Inhibits IFN-γ and IL-17 production and induce Tregs. Tregs, in turn, induce apoptosis, inhibit Th1 and T helper 17 immune responses, and produce 
IL-10 and TGF-β1
(82)
Regulate the expression of mRNAs for inflammatory cytokines such as IL-1, IL-10, IL-17, and IFN-γ, as well as levels of CD3+, CD4+, CD8+,  
and CD19+
(71)
Downregulate pro-inflammatory cytokines such as IL-1, IL-8, IL-, IL-17, and TNF-α (72)
Stimulate CD4(+) CD25(−) T cells and inhibit IFN-γ, IL-17, and IL-21. Work synergistically with IL-2 to produce CTLA-4 and FoxP3 Treg cells (49)
Antimicrobial properties
Upregulate the production of antimicrobial peptides such as cathelicidin and β-defensin and toll-like receptor 2 (3, 43)
Increase cathelicidin antimicrobial peptide and β-defensin expression (33, 80)
Regulate cathelicidin which activates the transcription of autophagy-related genes Beclin-1 and autophagy-related 5 in human monocytes (93)
Induce nucleotide-binding oligomerization domain 2 in monocytic and epithelial cells which then stimulates NF-kB and defensin β2 (33)
Activate peroxisome proliferator activated receptor-gamma and alpha, glucocorticoids and androgens (94)
Inhibit growth of the parasite Toxoplasma gondii possibly by inhibiting intra cellular proliferation in vivo and in vitro. Though the exact mechanisms 
are unknown
(95)
intestinal barrier maintenance
Control the expression of the tight junction proteins zonulin occluden-1, zonulin occluden-2, and can up regulate claudin 2 and 12 and down 
regulate cadherin-17 in the intestine
(75)
Inhibits a reduction in transepithelial electrical resistance between intestinal epithelial cells by pathogenic Escherichia coli O157:H7, which decreases 
intestinal permeability in epithelial cells
(72)
Increase transepithelial electrical resistance and decreasing LPS levels in Caco-2 cells that were either incubated or not with DSS (96)
Dysbiosis prevention
Attenuate irritable bowel disease through its anti-inflammatory properties and the prevention of dysbiosis (82)
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The DNA-bound VDR/RXR heterodimers also control genetic 
expression via histone modification, chromatin remodeling, and 
RNA polymerase II binding (83). Tapp et al. (84) suggested that 
vitamin D status and the consequent VDR activation influences 
age-related cytosine–guanine dinucleotide methylation islands 
of human rectal mucosa in healthy subjects and thus vitamin D 
has epigenetic protective effects against colorectal carcinogenesis. 
Similarly, another study associated vitamin D deficiency and 
VDR activity with changes in leukocyte DNA methylation (85).
In addition to the ligand 1,25(OH)2D3, VDR gene expres-
sion may be regulated by hormones such as estrogen, thyroid 
hormone, and glucocorticoids, which are likely able to alter 
VDR mRNA/protein levels (86), but also by dietary fatty acids 
(87) and the gut microbiota metabolites (88, 89). Despite these 
findings, more investigation is required to fully understand how 
VDR-mediated epigenetic changes, fatty acids, hormones, and 
microbiota metabolites can alter immune-related genes expres-
sion in various tissues.
Interaction between VDRs, Immune System,  
and Gut Microbiota
Most of the studies in humans have reported the effects that 
1,25(OH)2D3/VDR/RXR complex has on the innate immune cells 
(see Table 1). While investigators have made some progress there 
are still many unanswered questions about VDR as an immune 
system regulator in humans. Liu et  al. (90) showed that VDR 
levels were greatly reduced in human with Crohn’s disease, and 
that VDR deletion in mice led to severe colitis.
It is suggested that, on the one hand, VDRs negatively regulate 
bacteria-induced NF-kB activity in the gut (97). For example, a 
study in pregnant mice showed that maternal supplementation 
of 25 µg/kg vitamin D prior to an injection of 100 µg/kg of LPS-
activated VDR signaling, which inhibited the pro-inflammatory 
NF-kB p65 pathway and genetic expression of the inflammatory 
cytokines TNF-α, IL-Iβ, and IL-6 (98). On the other hand, VDRs 
may contribute to maintenance of intestinal barrier function by 
preventing increased intestinal permeability, dysbiosis, inflam-
mation, and a lack of immune tolerance in the gut (82). VDRs 
have been shown to regulate the expression of the tight junction 
proteins zonulin occluden-1, zonulin occluden-2 through the up 
regulation of claudin 2 and 12 and downregulation of adherin-17 
in the intestine. All of these proteins are essential for maintaining 
intestinal barrier function and thus immune homeostasis and the 
prevention of autoimmune diseases like IBD (75). In accordance, 
VDR KO mice have shown to be more susceptible to LPS-induced 
endotoxemia, have higher expressions of inflammatory cytokines 
8Clark and Mach Hygiene Hypothesis: Vitamin D, Autoimmunity
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 627
(e.g., TNF-α, IL-1a, IL-1β, IL-10, IL-21, and IFN-γ), and experi-
ence more weight loss, bleeding, ulceration, septic shock, and 
death compared to wild-type mice (80). Additionally, Zhao et al. 
(96) discovered that VDR expression increased transepithelial 
electrical resistance between the tight junctions and decreased 
LPS levels in Caco-2 cells that were both incubated or not with 
DSS leading to less intestinal permeability. Similarly, VDRs can 
also inhibit the reduction in transepithelial electrical resistance 
by the pathogenic Escherichia coli O157:H7, which thus decreases 
intestinal permeability in epithelial cells (72).
Additionally, Cantorna et al. (82) suggested that VDRs might 
regulate the gastrointestinal microbiota composition and prevent 
increased pathogenic proliferation in the gut by inhibiting Th1 
and Th17 cells (which produce IL-17 and IFN-γ) and inducing 
Tregs and AMPs. To further confirm the association between 
VDR and microbiota composition, Wang et  al. (99) analyzed 
gut microbiota data from a published VDR KO mouse model, 
confirming that the loss of VDR activity in mice substantially 
affects the Bray-Curtis beta diversity index in the gut (a measure 
of inter-individual microbiome variability). In humans, the same 
authors reported that VDR consistently influences individual 
bacteria taxa, such as Parabacteroides (99).
Animal models have been more promising showing the 
potential role of VDRs has on autoimmune diseases and 
microbiota composition inhibiting pathogenic proliferation in 
experimental murine colitis models. Wu et  al. (89) discovered 
that VDR KO mice presented higher levels of enteric Salmonella 
typhimurium, increased pro-inflammatory NF-kB activity 
and higher levels of mortality upon infection compared to the 
control group. Additionally, they observed that mice infected 
with Salmonella presented increased VDR protein activity in 
the upper and lower intestinal epithelial crypts independent of 
its ligand 1,25(OH)2D3. Similarly, Wu et  al. (97) reported that 
VDR KO mice had a down regulation at the transcription and 
translation level of the autophagy-related 16 like 1 (ATG16L1) 
gene, which resulted in impaired Paneth cell function, dysbiosis, 
and inflammation. Autophagy is a highly conserved process that 
is involved in intracellular homeostasis through the degradation 
and recycling of cytosolic contents and organelles, as well as in 
promoting the removal of intracellular microbes and immunity 
against infection (97). Remarkably, the same authors demon-
strated that the absence of intestinal epithelial VDR increased 
susceptibility to DSS-induced colitis, while decreasing butyrate-
producing bacteria, Butyrivibrio (97).
Other mice studies have shown the negative effects VDR 
deletion can have on gut homeostasis. Chen et al. (100) showed 
that VDR KO mice were more susceptible to the pathogen 
C. rodentium, whereas another group showed that VDR KO 
mice presented lower levels of Lactobacillus, increased levels 
of Clostridium and Bacteroides, as well as higher risk for infec-
tions, cancer, inflammation and other conditions compared 
with wild-type mice (101). Similarly, VDR KO mice had more 
bacteria from the Bacteroidetes and Proteobacteria phyla and 
fewer bacteria from the Firmicutes and Deferribacteres phyla in 
the feces compared to wild type (73). Recent evidence has shown 
that certain pathogenic microorganisms such as Salmonella typh-
imurium, Borrelia burgdorferi, Cytomegalovirus, Mycobacterium 
leprae, Aspergillus fumigatus, and Mycobacterium tuberculosis, 
the Epstein–Barr virus (3, 89, 102), and HIV (103) block or 
downregulate VDRs.
Interestingly, the gut microbiota has the capacity to produce 
secondary bile acids [e.g., lithocholic acid (LCA), glycine-
conjugated LCA, and 3-keto-LCA from 7α-dehydroxylated 
primary tauro-chenodeoxycholic acid] distinct from the liver 
that have the potential to bind to VDR (104). A very recent 
study by Wang et  al. (99) revealed through a genomic analysis 
in humans that Parabacteroides contained pathways involved 
in secondary bile acid metabolism and could thus indeed be 
associated with bile acid production. The interplay between VDR 
and Parabacteroides involved two genes associated with bile acid 
metabolism, the cytochrome P450 family 27 subfamily member 1 
(CYP27A1), and the nuclear receptor subfamily 5 group A mem-
ber 2 (NR5A2). Additionally, they found a positive correlation 
between Parabacteroides abundance and LCA concentrations in 
serum (99). The possibility that VDR acts as a key mediator in the 
gut–liver signaling axis and microbiota metabolism in humans 
motivates substantial new research directions (99).
Western lifestyle factors that affect the microbiome, such as 
the Western diet, antibiotics, toxins, and probiotics, could have 
the potential to affect the production of microbiota’s secondary 
bile acids, which in turn modify the function of VDR. Ongoing 
research is seeking to build models that predict the pattern of 
bile acids when certain microbiome members and metabolites 
are present in the gut, and the physiological effects they have on 
host VDRs and other transcription factors (104). Therefore, it is 
necessary to expand our knowledge about how VDRs relate to 
the human microbiome and whether those associations could be 
restricted to specific bacterial genera or species.
Altogether, these results illustrates that VDRs play a poten-
tially crucial role in controlling gut homeostasis and attenuating 
autoimmune symptoms that require further experiments in 
humans. For these reasons, Waterhouse et al. (102) believe that 
restoring VDR function, not just serum vitamin D levels, is key to 
preventing or improving autoimmune symptoms. Murine model 
experiments clearly demonstrate that VDR deletions might exag-
gerate colitis demonstrating that VDR acts as a master regulator 
of intestinal homeostasis and establishes a unifying link between 
VDR, autophagy, maintenance of intestinal barrier, the produc-
tion of AMPs, the intestinal microbiota, and innate immunity, all 
factors that have been implicated in the pathogenesis of autoim-
mune diseases.
VDR Polymorphisms and Improper VDR Function
Given the potential role VDRs have on immune responses and 
intestinal homeostasis, VDR genetic variants have also been 
studied as potential factor of autoimmune diseases since they may 
influence VDR activity. VDR is encoded by a large gene (>100 kb) 
mapped to chromosome 12q12-14. Its 14 exons spanning ~75 kb 
(105) exhibit a high number of polymorphisms, with at least 
4,710 reported variants, most of which are either undetectable 
or occur at a low frequency in the general population and appear 
to have no potential functional significance according to the 
dbSNP database 2016. Among the known VDR polymorphisms, 
the most common single-nucleotide polymorphisms (SNPs) that 
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influence VDR expression within the immune system include 
Bmsl (rs1544410), ApaI (rs7975232), TaqI (rs731236), and FokI 
(rs10735810) (106). BsmI, ApaI, and TaqI have been shown to 
be in strong linkage disequilibrium (LD) (107). Although their 
functional significances remain unknown, LD in combination 
with one or more functional polymorphisms elsewhere in the 
VDR gene are believed to explain observed associations between 
the VDR gene and autoimmune diseases (108).
A case-controlled study including 160 patients with MS and 
150 healthy controls revealed the protective role of TT genotype 
of TaqI (ORs| < |1), CC genotype of Apal, and GG genotype of 
BsmI (ORs| <  |1), suggesting that VDR polymorphisms seem 
to have a notable connection with MS pathogenesis; however, 
studies in big population that analyze the functional work on 
the gene structure and its function are needed (109). Another 
study in 158 European Caucasians with ulcerative colitis, 245 
with Crohn’s disease and 164 cadaveric renal allograft donor 
controls demonstrated that there were significantly more people 
who were homozygous for the TaqI polymorphism at codon 
352 of exon 8 (genotype tt) among patients with Crohn’s disease 
(frequency 0.22) than patients with ulcerative colitis (0.12) or 
controls (0.12) (110).
Recently, Wang et al. (99) found that variants in the VDR gene 
were among the 42 significant loci and accounted for 0.75% of 
the microbiota variation in a cohort of 1,812 northern-Germans. 
They have shown for the first time that genetic variation at the 
VDR locus significantly impacts microbiota composition in the 
gut, although large sample sizes and adequate statistical power are 
needed in future assessments.
The absence of studies with large cohorts in this field does 
not mean that VDR SNPs have no biological function or that all 
positive associations are a case of false causation. It does show, 
however, that discovering the underlying biological functions of 
these SNPs, if they exist, will not be an easy task. Future case–con-
trol studies will have to be carefully conducted and have sufficient 
power in order to detect associations much weaker than those 
currently postulated.
The increasing interest in the epigenetic control of VDR 
regulation and possible significance for diseases (86) has shown 
that the VDR promoter region can be methylated which may 
affect its function. The promoter region of the VDR gene lies in 
a GpC-rich island and contains strong regulatory elements for 
its transcriptional activity (111). Disruption of promoter activity 
by DNA methylation is an epigenetic inactivating mechanism 
frequently observed in tumor-suppressor genes (112). Genetic 
variants of these sites might affect the methylation boundaries 
of the promoters, which could be the most under-explored 
aspect of VDR gene regulation and its role in health and disease 
(113). More studies are needed to fully understand the role VDR 
function and VDR genetic and epigenetic modifications play in 
preventing autoimmune diseases and dysbiosis.
CONCLUSiON
Several studies have positively correlated vitamin D deficiency 
with autoimmune diseases. Promising studies in humans have 
demonstrated that vitamin D3 supplementation can lead to 
an increase in beneficial bacteria, such as Ruminococcaceae, 
Akkermansia, Faecalibacterium, and Coprococcus, which can 
attenuate autoimmune responses. In mice, vitamin D3 has also 
been shown to modulate the gut microbiota toward a healthier 
composition by inducing AMPs such as angiogenin-4 and 
E-cadherin as well as autophagy in colitis models. The VDR is 
mainly activated by the binding of 1,25(OH)2D3, and the VDR 
complex regulates ~3% of the human genome. Studies in VDR KO 
mice have demonstrated that intestinal VDRs play an important 
role in regulating intestinal inflammation, autophagy, the pro-
duction of AMPs, and the susceptibility to pathogenic infection. 
Furthermore, evidence is emerging that VDR is a key component 
in maintaining gut intestinal barrier function and preventing 
dysbiosis, which can attenuate inflammation. Recent studies 
suggest that VDR is regulated not only by vitamin D but also 
by enteric bacteria and other hormonal compounds, including 
the secondary bile acids produced by gut bacteria. The complex 
regulatory network that controls VDR activity including genetic 
and epigenetic modifications in its promoter region and how that 
affects the immune system remains largely unknown. Insights 
gained from understanding how the VDR pathway is involved 
in regulating the immune system and changing microbiome 
diversity may serve as a paradigm for understanding the rise in 
autoimmune diseases.
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